A team of >300 employees
in >30 countries
The greatest minds in biotechnology and machine learning are at work at SOPHiA GENETICS, continuously honing our algorithms, offers and services for the benefit of clinical researchers worldwide. About 80% of our organization holds a PhD, ranging anywhere from Cell Biology to Computer Science. This international and dedicated team is the key to our current success and is the promise of an even greater future ahead for us and the world of Data-Driven Medicine.
Founder and CEO
Dr. Jurgi Camblong is a visionary entrepreneur who is pioneering the Data-Driven Medicine movement around the world. He is a Molecular Biologist (published in Cell, Science & Nature), has a PhD in Life Sciences from the University of Geneva, and an EMBA in Management of Technology from EPFL/HEC Lausanne. In 2011, he founded SOPHiA GENETICS with Dr. Pierre Hutter and Prof. Lars Steinmetz. He has since successfully led the development of the company, listed among the 50 Smartest Companies by the MIT Technology Review. Dr. Camblong has been a member of the Advisory Council on Digital Transformation to the Swiss Government, and was personally recognized by EY as Emergent Entrepreneur of the Year in 2017.
SVP - Chief Commercial Officer
Bram Goorden is an accomplished commercial executive with 20 years of experience in life sciences. He joined SOPHiA GENETICS in 2020 as Chief Commercial Officer and also serves as the Head of North America based in Boston, Massachusetts. He comes from Foundation Medicine Inc. (Cambridge, MA), where he held the role of VP International Business and Partnering in charge of expanding the global footprint of the company to become a leader in precision medicine . Prior to that he was General Manager, Head of Therapeutics with Prometheus Labs (San Diego, CA), a Nestle Health Science company, and has held global roles of increasing responsibility in strategic and operations management with Eli Lilly and UCB Pharma. He is passionate about the role of data in improving patient care and he has had the opportunity to successfully launch novel solutions in different areas of healthcare. Bram serves on the boards of several companies and associations and is a former member of patient advocacy and philanthropic healthcare organizations.
He has a BA from the University of Bologna - Italy, an MSc from the University of Antwerp – Belgium in Commercial Engineering. He has followed executive educations at the Kellogg School of Management and Harvard Business School.
SVP - Chief Business Officer
Growing up in Canada, Lara developed an early interest in understanding the role of genetics in common diseases. This took her from studying genetics of Multiple Sclerosis at the University of Western Ontario to joining the Wellcome Trust Centre for Human Genetics at the University of Oxford, UK.
Lara joined SOPHiA GENETICS in 2020, but first joined industry 20 years ago as a Scientist at Roche Pharma based in Basel, Switzerland. She has held several positions spanning Pharma clinical drug development, business analytics and strategic marketing in the global organization as well as sales and operational marketing positions in the Canadian affiliate.
In 2009, Lara moved to Roche Molecular Diagnostics in California as the Lifecycle Leader responsible for the Genomics and Oncology IVD product portfolio and pipeline, launching several companion diagnostics globally. Lara then became the General Manager of Roche Diagnostics New Zealand Ltd where she grew sales above market for 4 consecutive years. Returning to the Bay Area, Lara then joined the newly formed Roche Sequencing Solutions team where she was the VP responsible for Non-Invasive Prenatal Testing and the Nanopore Sequencer before being appointed Chief Commercial Officer.
SVP - Global Head of Sales, Healthcare Division
SVP - Chief Financial Officer
Valentin Matillon joined SOPHiA GENETICS in 2018 as Chief Financial Officer. He is a seasoned finance executive with over 20 years of leadership experience in IT, Telecommunications and MedTech companies. He has held a number of senior finance management positions at SITA, Electronic Arts and Hewlett-Packard, including Group CFO, senior finance director in charge of corporate finance, financial planning & analysis, and performance management programs. Most recently, as senior finance director at the Hobart Group, Valentin led the corporate finance, financing & accounting operations team.
As CFO, Valentin focuses on increasing shareholder value by driving global financial excellence and long-term sustainability. In addition to leading the Finance organization, Valentin is also in charge of the Legal department and Business Development activities. He received his Finance B.A. from Institut des Hautes Etudes Economiques et Commerciales de Paris and his MS from Ecole Centrale de Paris, France.
"It is not the strongest of the species that survives, but the most adaptable" - Charles Darwin
SVP - Chief Medical Officer
Dr. Philippe Menu (MD-PhD, MBA) brings a unique blend of medical expertise across clinical medicine, fundamental research in molecular biology and business management consulting. He joined SOPHiA GENETICS in 2020 from McKinsey & Company, where he had spent the last 8 years serving dozens of clients in the biopharma sector, advising global pharmaceutical companies, mid-size players and biotechs alike across the pharma value chain with a major focus on innovative therapies and diagnostics in oncology and rare diseases. Philippe obtained his MD and PhD from the University of Lausanne, and his MBA in Life Sciences from the Open University Business School.
VP - Business Development
Kevin Puylaert is VP Business Development. His focus is on broadening the company’s reach within the clinical research industry across the region while managing business development and partnerships. His commitment and entrepreneurial spirit has been pivotal in accelerating the adoption of SOPHiA AI around the world. Prior to his current role he led the company’s business development activities outside of Europe and was responsible for building sales teams across APAC, LATAM and Africa. Before joining the company, Kevin was a lead Strategic & Development Project Manager at the Clinique Universitaire Saint-Luc in Belgium. He has a Bachelor’s Degree in Business Engineering focused on production and logistics from the University of Leuven in Belgium. He completed his Masters in Science from the Louvain School of Management where is specialized in Supply Chain Management and International Business.
SVP - Chief People Officer
Manuela Da Silva Valente is a seasoned Human Resources Executive with over 20 years experience working in international companies. Manuela has joined SOPHiA GENETICS in January 2019 from IQVIA (formerly Quintiles and IMS Health Inc.), a Human Data Science company, where she held a number of senior Human Resources roles with most recently the position of Global Senior Human Resources Director. Prior to this, she worked for several years at Outcome Sciences, where she successfully established the European operations and led the organization through the acquisition by Quintiles, a Global Clinical Research Organization.
Manuela obtained a Bachelor Degree in Business Administration from the Business Management School of Zurich and a Management & Human Resources Diploma from CEFCO Lausanne.
Manuela has extensive experience in aligning people strategies with business objectives and driving significant organizational and cultural changes, by focusing on talent development and employee engagement.
Daan Van Well
SVP - General Counsel
Daan van Well is a legal professional with more than 20 years of experience in top tier private practice, in-house and consulting roles, and has extensive experience in legal, governance and compliance matters. Prior to joining SOPHiA GENETICS in June 2019, he was the Head of Legal at PwC in Geneva, Switzerland. Daan has also held several in-house legal positions for international food retailer Ahold (currently Ahold-Delhaize). He started his career as a lawyer at international law firm Loyens & Loeff in Rotterdam, The Netherlands. Daan holds an LL.M in Dutch civil law from Utrecht University and an Executive MBA in Management and Corporate Finance from HEC Lausanne. His peers have called him driven and motivated to promote team-building environments.
SVP - Chief Technology Officer
Dr. Zhenyu Xu is a genome scientist with a background in molecular and computational biology. He holds a Master’s degree from Cambridge University in computational biology, and obtained his PhD at the European Molecular Biology Laboratory (EMBL) where he focused on the transcriptome landscape of yeast. His PhD work systematically characterized the non-coding transcripts in yeast which lead to the unveiling that in a majority of cases, transcriptions are bidirectional. Dr. Xu is among the most experienced bioinformaticians worldwide in clinical NGS data analysis. He joined SOPHiA GENETICS in 2012 and is the leader of the technology team who developed SOPHiA – the universal technology for Data-Driven Medicine. The AI powers SOPHiA DDM®, an advanced SaaS analytics platform for clinical genomics, recognized and widely used in hundreds of hospitals across the world.
SVP - Chief Operating Officer
Dr. Sergei Yakneen is an accomplished leader, technologist, and scientific researcher who brings a wealth of experience in financial technology, e-commerce, and cancer research. He joined SOPHiA GENETICS in September of 2019 after most recently working at the European Molecular Biology Laboratory in Heidelberg, Germany. He graduated from the University of Toronto with a degree in Computer Science and Mathematics and completed his PhD in Genomics and Computer Science at Heidelberg University. Over the past 15 years he’s led the Product Development and Professional Services groups of fin-tech startups, and launched Amazon.com’s first Software Engineering organization in the Toronto area. He led the technical working group of the world’s largest international cancer genome analysis project, the Pan Cancer Analysis of Whole Genomes, and devised new methods for analysis of genomic data at scale. Since 2013 Sergei has been focused on bringing the power of large-scale distributed computing to bear down on some of the hardest problems in cancer research.
BOARD OF DIRECTORS
Troy Cox is a pioneer in the precision medicine revolution. Former CEO of Foundation Medicine (FMI) - acquired by Roche in 2018 - Troy is today making a difference in patient’s lives by serving on corporate boards of innovative companies in the Biopharma, Diagnostic, and Tech industries. He is also committing his support to patient-focused non-profit organizations.
In June 2019, Troy joined SOPHiA GENETICS’ Board of Directors to help the organization further advance Data-Driven Medicine.
Prior to Foundation Medicine, Troy served as Senior Vice President and Officer at Genentech where he led US BioOncology for a period of unprecedented growth, participating in the launch of nearly half of the products from the world’s oncology leader. Other notable experiences include UCB, Sanofi-Aventis and Schering-Plough.
Troy’s expertise spans across strategy, general management, commercial, and R&D. His pharmaceutical career began as a Sales Representative after earning his MBA at the University of Missouri. He also received a BBA in Finance from the University of Kentucky.
Founder and CEO
Dr. Jurgi Camblong is a visionary entrepreneur who is pioneering the Data-Driven Medicine movement around the world. He is a Molecular Biologist (published in Cell, Science & Nature), has a PhD in Life Sciences from the University of Geneva, and an EMBA in Management of Technology from EPFL/HEC Lausanne. In 2011, he founded SOPHiA GENETICS with Dr. Pierre Hutter and Prof. Lars Steinmetz, and has since successfully been leading the development of the company, listed by the MIT Technology Review amongst the 50 smartest companies in 2017. Dr. Camblong is a member of the Advisory Council on Digital Transformation to the Swiss Federal Government, and was personally recognized by EY as Emergent Entrepreneur of the Year in 2017.
Antoine Duchateau is a successful entrepreneur. He started his career with IBM Belgium as software engineer and sales executive for the financial sector in Brussels, then in 1981 joined the British BIS Banking Systems Group (BIS) in London, a worldwide leader in core banking application software, as Managing Director for Europe, then Chief Operating Officer. In 1995 he founded Odyssey Financial Technologies (OFT), which became over the years, the worldwide leader in mid-front office application software for the private banking sector. Under his direction as CEO and Chairman the company revenue grew to over $70M with 600 employees. In 2010, he executed the sale of Odyssey to Temenos Group AG. Following the sale of OFT, Antoine Duchateau decided to help start up and small to medium size enterprises by bringing his expertise. He was appointed Chairman of the Board of SOPHiA GENETICS in spring 2013.
Dominique Mégret is head of Swisscom Ventures, which he started in 2007. He joined Swisscom in 2002 as head of the Group Strategy unit. Previously, Dominique Mégret was a tech entrepreneur in the United Kingdom, a strategy consultant in the European telecom industry and country manager for an IT company in Germany. He holds an MBA from Insead.
Independent Board Member
Dr. Vincent Ossipow, CFA is Venture Partner at Omega Funds and brings 16 years of healthcare investment experience in public and private companies. Previously, Vincent worked with Sectoral Asset Management, a healthcare institutional investor, as a Partner for Private Equity. From 2000 to 2006 he worked as a research fellow at the University of Geneva on the molecular basis of brain function where he obtained a Ph.D. in molecular biology. Vincent trained as a postdoctoral fellow (Hoffman-La-Roche and Human Frontier Science Program fellow) in Geneva and at the National Cancer Institute NCI in Bethesda, Maryland, and completed a Certificate in International Finance and Global Markets at the Georgetown University School of Business in Washington, D.C.
Michael Schenck is an experienced venture capital and private equity investor and currently works with Alychlo, the investment firm of Belgian entrepreneur Marc Coucke.Previously, Michael was investment manager at Waterland Private Equity where he worked closely with a number of entrepreneurs to help realize their growth ambitions. He started his career in corporate finance in France and has worked both as a volunteer and entrepreneur in Africa. Michael holds Master’s Degrees in business and management from Erasmus University Rotterdam and HEC Paris.
Milton G. Silva-Craig is a successful leader who has demonstrated expertise in growing and scaling businesses in various fields of healthcare, including IT, medical imaging and quality data management, with 25 years of experience. He has been the Chief Executive Officer of Q-Centrix for the past five years, recently leading the company through a successful sale from private equity firm Sterling Partners to TPG Growth. Prior to Q-Centrix, he served as president of TransUnion’s healthcare business unit, where, he developed and executed a strategic business plan focused on repositioning and growing TransUnion in the healthcare marketplace, resulting in an eightfold increase.. Prior to TransUnion, Silva-Craig served as the President and Chief Operating Officer at Emageon Inc., leading the company’s strategic direction and operations. He grew revenues from several hundred thousand dollars to more than $100 million, and eventually led Emageon through its initial public offering on NASDAQ in 2005. He also held executive positions at General Electric Medical Systems. Silva-Craig earned a J.D. from the University of Wisconsin School of Law in Madison and obtained his M.B.A. and B.A. from the University of Wisconsin – Madison.
James is a partner at Balderton Capital, Europe’s largest venture fund focussed on growth stage technology companies. James works with companies in fields ranging from biotech, manufacturing, AR/VR and mobile, and has been an investor in companies acquired by Microsoft and Amazon. He holds board and advisory positions with 8 technology companies. Prior to Balderton, James helped launch one of the UK's first Social Impact Funds, and has worked for both the British Government and McKinsey & Company. He holds an MA Oxon from Oxford Univeristy.